Study guide

22.4 Coagulation Cascade & Inherited Bleeding Disorders

MRCP UK

Track your progress as you read

Finished sections get a check mark.

1 MRCP(UK) Part 1: Exam Overview, Blueprint & Strategy

1.1 Part 1 Format, Delivery and Fees 1.2 The Official Blueprint and Mark Allocation 1.3 Scaled Scoring, Attempt Limits and Best-of-Five Technique

2 Clinical Sciences: Cellular, Genetic & Molecular Medicine

2.1 Organelles, Cytoskeleton & Membrane Transport 2.2 Cell Cycle Control, Apoptosis & Cell Signalling 2.3 Mendelian & Non-Mendelian Inheritance 2.4 Trinucleotide Repeat Disorders & Chromosomal Abnormalities 2.5 Purine, Pyrimidine Metabolism & the Porphyrias 2.6 Glycogen, Lipid Storage & Amino Acid Disorders

3 Clinical Sciences: Anatomy, Physiology & Immunology

3.1 Clinical & Cross-Sectional Anatomy 3.2 Systemic Clinical Physiology & Homeostasis 3.3 Clinical Immunology & Hypersensitivity Reactions

4 Clinical Sciences: Statistics, Epidemiology & Trial Design

4.1 Study Designs & Evidence Hierarchy 4.2 Diagnostic Testing, Screening & Predictive Values 4.3 Statistical Analysis & Risk Quantification

5 Clinical Pharmacology, Therapeutics & Toxicology

5.1 Pharmacokinetics & Pharmacodynamics 5.2 Cytochrome P450 Systems & High-Risk Drug Interactions 5.3 Adverse Drug Reactions & Therapeutic Drug Monitoring 5.4 Paracetamol & Salicylate Poisoning 5.5 Toxidromes, Antidotes, Carbon Monoxide & Toxic Alcohols

6 Cardiology: Coronary Artery Disease & Heart Failure

6.1 Acute Coronary Syndromes & Myocardial Infarction 6.2 Heart Failure & Cardiomyopathies 6.3 Cardiac Assessment & ECG Interpretation

7 Cardiology: Arrhythmias, Valvular & Pericardial Disease

7.1 Atrial Fibrillation, Narrow & Broad Complex Tachycardias 7.2 Bradyarrhythmias, Conduction Block & Antiarrhythmic Drugs 7.3 Valvular Heart Disease & Murmur Interpretation 7.4 Infective Endocarditis 7.5 Pericardial & Acute Aortic Diseases

8 Respiratory Medicine: Airway & Parenchymal Lung Disease

8.1 Asthma: Diagnosis, Chronic Management & Acute Attacks 8.2 COPD: GOLD Staging, Stable Management, Exacerbations & NIV 8.3 Interstitial Lung Disease & Sarcoidosis 8.4 Respiratory Infections & Bronchiectasis

9 Respiratory Medicine: Vascular, Pleural & Sleep Disorders

9.1 Venous Thromboembolism & Pulmonary Embolism 9.2 Pleural Effusion & Pneumothorax 9.3 Respiratory Failure & Sleep-Disordered Breathing

10 Gastroenterology: Luminal Gastrointestinal Disease

10.1 GORD, Barrett's Oesophagus & Oesophageal Motility Disorders 10.2 Peptic Ulcer Disease, Helicobacter pylori & Zollinger-Ellison Syndrome 10.3 Crohn's Disease, Ulcerative Colitis & Extraintestinal Manifestations 10.4 IBD Medical Therapy, Coeliac Disease & Malabsorption 10.5 Acute Upper Gastrointestinal Bleeding: Risk Scores, Ulcer & Variceal Haemorrhage 10.6 Lower Gastrointestinal Disorders & Colonic Neoplasia

11 Gastroenterology: Liver, Biliary & Pancreatic Disease

11.1 Viral Hepatitis A to E 11.2 Autoimmune Hepatitis & Metabolic Liver Disease 11.3 Cirrhosis & Complications of Portal Hypertension 11.4 Cholestatic Liver Disease: PBC and PSC 11.5 Gallstone Disease, Biliary Sepsis & Pancreatitis

12 Endocrinology & Diabetes: Diabetes & Thyroid

12.1 Diabetes: Diagnostic Thresholds, Classification & Pathophysiology 12.2 NICE-Directed Type 2 Therapy & Microvascular Complications 12.3 Acute Diabetic Emergencies (DKA & HHS) 12.4 Thyrotoxicosis, Thyroiditis & Management of Hyperthyroidism 12.5 Hypothyroidism, Subclinical Disease & Thyroid Nodules

13 Endocrinology & Diabetes: Adrenal, Pituitary & Calcium

13.1 Hypopituitarism, Pituitary Apoplexy & Hyperprolactinaemia 13.2 Acromegaly, Diabetes Insipidus & SIADH 13.3 Cushing's Syndrome: Aetiology, Screening & Localisation 13.4 Adrenal Insufficiency & Endocrine Hypertension 13.5 Calcium Regulation & Hypercalcaemia 13.6 Hypocalcaemia & Metabolic Bone Disease

14 Renal Medicine: AKI, Glomerular & Tubulointerstitial Disease

14.1 Acute Kidney Injury & Chronic Kidney Disease 14.2 Nephrotic and Nephritic Syndromes & Primary Glomerular Disease 14.3 Rapidly Progressive Glomerulonephritis 14.4 Tubulointerstitial & Inherited Renal Diseases

15 Renal Medicine: Fluid, Electrolytes & Acid-Base Balance

15.1 Sodium & Water Disorders 15.2 Potassium, Magnesium & Phosphate Disorders 15.3 Acid-Base Disorders & Blood Gas Analysis

16 Neurology: Cerebrovascular, Headache & Demyelinating Disease

16.1 Stroke Classification, Brainstem Syndromes & Hyperacute Reperfusion 16.2 Secondary Prevention, TIA, Carotid Surgery & Intracranial Haemorrhage 16.3 Headache Disorders & Cranial Neuralgias 16.4 Multiple Sclerosis & Central Demyelinating Diseases

17 Neurology: Epilepsy, Movement Disorders & Neuromuscular Disease

17.1 Epilepsy & Acute Seizures 17.2 Movement Disorders & Cognitive Impairment 17.3 Neuromuscular Junction & Peripheral Nerve Disorders

18 Rheumatology: Inflammatory Arthritis & Connective Tissue Disease

18.1 Rheumatoid Arthritis: Pathophysiology, Clinical Features & Diagnosis 18.2 DMARDs, Biologics & Their Toxicities 18.3 Seronegative Spondyloarthropathies 18.4 Systemic Lupus Erythematosus & Drug-Induced Lupus 18.5 Systemic Sclerosis & Scleroderma Renal Crisis 18.6 Sjogren's Syndrome & Inflammatory Myopathies

19 Rheumatology: Systemic Vasculitis & Crystal Arthropathy

19.1 Vasculitis Classification, Large and Medium Vessel Disease 19.2 ANCA-Associated and Immune Complex Small Vessel Vasculitis 19.3 Gout & Calcium Pyrophosphate Deposition Disease

20 Infectious Diseases & Tropical Medicine

20.1 Sepsis-3 Definitions & the Sepsis Six 20.2 Bacterial Meningitis, CSF Interpretation & Toxic Shock Syndrome 20.3 Tuberculosis: Pathogenesis & Clinical Manifestations 20.4 Tuberculosis: Diagnosis & Anti-Tuberculous Therapy 20.5 HIV Infection & Opportunistic Diseases 20.6 Malaria: Species, Life Cycle & Severe Disease 20.7 Enteric Fever, Arboviral Infection & Tissue Parasites

21 Haematology: Anaemias & Red Cell Disorders

21.1 MCV-Based Diagnostic Approach to Anaemia 21.2 Haemolytic and Autoimmune Haemolytic Anaemias 21.3 Membranopathies, Enzymopathies, PNH & Sickle Cell Disease

22 Haematology: Malignancy, Coagulation & Transfusion Medicine

22.1 Acute Leukaemias 22.2 Chronic Leukaemias & Myeloproliferative Neoplasms 22.3 Lymphomas & Plasma Cell Dyscrasias 22.4 Coagulation Cascade & Inherited Bleeding Disorders 22.5 Thrombocytopenia & Thrombotic Microangiopathies 22.6 Transfusion Products & Acute Transfusion Reactions

23 Psychiatry in General Medicine

23.1 Mood & Psychotic Disorders in Medical Patients 23.2 Psychiatric Emergencies & Substance Misuse 23.3 Mental Capacity & UK Mental Health Law

24 Geriatric Medicine

24.1 Comprehensive Geriatric Assessment, Frailty, Delirium & Falls 24.2 Polypharmacy, Deprescribing & Pressure Ulcers

25 Dermatology

25.1 Inflammatory Skin Disease, Immunobullous Disorders & Severe Drug Eruptions 25.2 Cutaneous Malignancy

26 Oncology & Palliative Medicine

26.1 Neutropenic Sepsis, Spinal Cord Compression & SVC Obstruction 26.2 Hypercalcaemia of Malignancy & Tumour Lysis Syndrome 26.3 Palliative Care & End-of-Life Symptom Control

27 Medical Ophthalmology

27.1 The Acute Red Eye & Sudden Painless Visual Loss 27.2 Retinopathy in Systemic Disease

22.4 Coagulation Cascade & Inherited Bleeding Disorders

Key Takeaways Explain This Topic AI

An isolated prolonged APTT that corrects on mixing suggests factor deficiency such as haemophilia; failure to correct suggests an inhibitor or lupus anticoagulant.

Von Willebrand disease is autosomal dominant, causes mucocutaneous bleeding with a prolonged APTT and reduced factor VIII, and type 1 responds to desmopressin.

Haemophilia A and B are X-linked recessive and cause haemarthrosis and deep muscle bleeding with a normal prothrombin time.

Last updated: September 2026

Hemostasis, thrombosis, and transfusion medicine constitute critical domains of acute internal medicine tested extensively in the MRCP(UK) Part 1 examination. Candidates must master the physiological pathways of platelet plug formation and coagulation cascade serine proteases, distinguish inherited bleeding diatheses, manage life-threatening microangiopathies and thrombotic emergencies, and rapidly recognize and treat adverse transfusion reactions.

1. Hemostasis & Coagulation Cascade Architecture

Hemostasis is divided into two interdependent physiological phases: primary hemostasis (platelet plug formation) and secondary hemostasis (fibrin clot generation). The Hemostatic Cascade

  • |
  • +---------------------------+---------------------------+
  • | |
  • Primary Hemostasis Secondary Hemostasis
  • (Platelets & vWF) (Coagulation Cascade)
  • | |
  • 1. Adhesion (vWF -> GpIb) +--------+--------+
  • 2. Activation (ADP, TxA2) | |
  • 3. Aggregation (GpIIb/IIIa -> Fibrinogen) Intrinsic Extrinsic
  • | (XII, XI, IX, VIII) (Tissue Factor, VII)
  • Defect: Mucocutaneous bleeding | |
  • (Petechiae, epistaxis, menorrhagia) [ aPTT ] [ PT ]
  • +--------+--------+
  • |
  • Common Pathway
  • (X, V, II, I)
  • [ Both Prolonged ]
  • Primary Hemostasis

Endothelial Injury & Platelet Adhesion: Vascular injury exposes subendothelial type I/IV collagen and von Willebrand factor (vWF). Circulating platelets adhere to exposed subendothelial vWF via the Glycoprotein Ib-IX-V (GpIb) receptor complex on the platelet surface.

Platelet Activation & Secretion: Adherent platelets undergo shape change (discoid to pseudopodial) and degranulate:

Dense granules: Release adenosine diphosphate ( ADP ; activates P2Y12 receptors) and calcium (mandatory for clotting factor assembly).

Alpha granules: Release vWF, fibrinogen, factor V, and platelet factor 4 (PF4).

Thromboxane A2 (TxA2): Platelet membrane arachidonic acid is converted by cyclooxygenase-1 (COX-1) and thromboxane synthase into TxA2, a potent platelet activator and local vasoconstrictor.

Platelet Aggregation: Activation induces a conformational change in the Glycoprotein IIb/IIIa (GpIIb/IIIa / integrin aIIb-b3) receptor complex, exposing high-affinity binding sites for dimeric fibrinogen (and vWF). Fibrinogen forms bridges between adjacent platelets, assembling the primary, friable hemostatic plug.

Clinical Manifestations of Primary Hemostatic Defects: Mucocutaneous bleeding: Petechiae (pinpoint capillary haemorrhages, pathognomonic of thrombocytopenia), purpura, superficial ecchymoses, recurrent epistaxis, gingival bleeding, menorrhagia, and immediate, persistent oozing following minor cuts or dental extractions.

Secondary Hemostasis

Secondary hemostasis stabilizes the primary platelet plug through sequential enzymatic activation of circulating plasma serine proteases, culminating in thrombin generation and insoluble crosslinked fibrin mesh formation.

Intrinsic Pathway (Contact Activation):

Initiated when Factor XII (Hageman factor) contacts negatively charged subendothelial surfaces. Factor XIIa activates Factor XI -> XIa activates Factor IX. Factor IXa complexes with its activated cofactor Factor VIIIa , phospholipid, and calcium to form the "tenase complex" , which activates Factor X.

Monitored by: Activated Partial Thromboplastin Time (aPTT) (normal range: 25–35 seconds).

Extrinsic Pathway (Tissue Factor Pathway):

Initiated when subendothelial Tissue Factor (TF / thromboplastin) is exposed to circulating blood at the injury site. TF complexes with and activates Factor VII . The TF-VIIa complex directly cleaves and activates Factor X.

Monitored by: Prothrombin Time (PT) (normal range: 11–14 seconds) and International Normalized Ratio (INR) .

Common Pathway:

Factor Xa complexes with activated cofactor Factor Va , calcium, and phospholipid to form the "prothrombinase complex" . Prothrombinase cleaves Prothrombin (Factor II) into active Thrombin (Factor IIa) . Thrombin then cleaves soluble Fibrinogen (Factor I) into insoluble Fibrin monomers (Factor Ia) . Finally, Factor XIIIa (fibrin-stabilizing factor, activated by thrombin) covalently crosslinks fibrin polymers via isopeptide bonds, cementing the stable hemostatic clot.

Crucial Diagnostic Rule: Deficiencies, consumptive loss, or pharmacological inhibition of common pathway factors (X, V, II, or I) produce prolongation of BOTH the PT and the aPTT .

Clinical Manifestations of Secondary Hemostatic Defects: Deep tissue bleeding: Spontaneous haemarthroses (bleeding into joints, especially knees, elbows, ankles), intramuscular haematomas, retroperitoneal haemorrhage, and characteristically delayed bleeding hours or days following trauma or surgical interventions.

  • 2. Inherited Bleeding Disorders
  • Haemophilia A & B

Genetics: Both are X-linked recessive disorders, predominantly affecting males. Females are usually asymptomatic carriers (although extreme lyonization / skewed X-chromosome inactivation can result in mild clinical bleeding in females).

Haemophilia A: Deficiency of Factor VIII (accounts for ~80% of all haemophilia cases; incidence ~1 in 5,000 live male births).

Haemophilia B (Christmas Disease): Deficiency of Factor IX (incidence ~1 in 30,000 live male births).

Laboratory Profile: Isolated prolongation of the aPTT with completely normal PT/INR, normal platelet count, and normal bleeding time / PFA-100 .

50:50 Mixing Study: Mixing patient plasma 1:1 with normal pooled plasma results in complete correction of the prolonged aPTT , confirming an intrinsic factor deficiency (failure to correct indicates a circulating inhibitor or lupus anticoagulant).

Clinical Classification by Baseline Factor Activity:

Severe (<1% normal activity / <0.01 IU/mL): Characterized by frequent spontaneous haemarthroses (starting at walking age) and deep muscle haematomas. Recurrent joint bleeding leads to chronic haemophilic arthropathy (synovial hypertrophy, cartilage loss, joint destruction).

Moderate (1–5% activity): Bleeding occurs with minor trauma or minor surgery; rare spontaneous bleeds.

Mild (5–40% activity): Often diagnosed late in adulthood following major trauma, dental extractions, or major surgery.

Management:

On-demand or regular prophylactic replacement with recombinant Factor VIII or Factor IX .

Emicizumab: A humanized, bispecific monoclonal antibody that binds simultaneously to activated Factor IXa and Factor X, mimicking the cofactor activity of Factor VIII. Administered subcutaneously every 1–4 weeks; highly effective for Haemophilia A prophylaxis, including in patients with neutralizing anti-Factor VIII alloantibodies (inhibitors).

Mild Haemophilia A responds to Desmopressin (DDAVP) , which stimulates the release of endogenous Factor VIII stores from endothelial Weibel-Palade bodies.

von Willebrand Disease (vWD)

Epidemiology & Genetics: The most common inherited bleeding disorder in humans (estimated prevalence ~1% of the general population). Primarily autosomal dominant (Types 1 and 2), with rare severe autosomal recessive inheritance (Type 3).

Dual Physiological Role of vWF:

Facilitates primary hemostasis by anchoring platelets to subendothelial collagen (via GpIb);

Facilitates secondary hemostasis by acting as the specific carrier protein for circulating Factor VIII , protecting it from rapid proteolytic degradation (extending Factor VIII half-life from ~2 hours to >12 hours).

Classification:

Type 1 (75–80%): Autosomal dominant quantitative partial reduction of structurally normal vWF. Mild-to-moderate mucocutaneous bleeding.

Type 2 (15–20%): Qualitative functional defects in vWF (subtypes 2A, 2B, 2M, 2N).

Type 3 (<5%): Autosomal recessive virtually complete absence of vWF; manifests with severe mucocutaneous bleeding AND spontaneous haemarthroses (because Factor VIII levels drop to <5%).

Laboratory Features: Bleeding time / PFA-100 is prolonged; PT is strictly normal ; aPTT is normal or prolonged (prolongation depends on whether Factor VIII levels are reduced below 30–40%); platelet count is normal (except in type 2B, where gain-of-function induces mild thrombocytopenia).

Diagnostic Panel: Plasma vWF antigen (quantitative), vWF ristocetin cofactor activity (vWF:RCo; functional ability to agglutinate platelets), and Factor VIII coagulant activity.

Therapeutic Strategy:

Tranexamic acid (antifibrinolytic; competitive inhibitor of plasminogen activation) for mild mucosal bleeding, menorrhagia, and dental procedures.

Desmopressin (DDAVP): Stimulates rapid exocytosis of pre-formed endogenous vWF and Factor VIII stored in endothelial Weibel-Palade bodies . Effective in Type 1 vWD. CONTRAINDICATED in Type 2B vWD (triggers catastrophic intravascular platelet clumping and profound thrombocytopenia); INEFFECTIVE in Type 3 vWD (no intracellular stores exist).

Intermediate-purity, plasma-derived Factor VIII/vWF concentrates (e.g. Haemate-P, Voncento) or recombinant vWF for Type 3 vWD, severe Type 2, or major surgery.